Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Exclusion Criteria

• •Participants with Secondary ITP
• •Participants with Evans syndrome or history of myelodysplastic syndrome
• •Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy.
• •Participants with history of solid organ transplant
• •Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP
• •Participant received advanced therapy for ITP or was splenectomized
• •Pregnancy or nursing The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.